FY2025 EPS Estimates for IDYA Lifted by Cantor Fitzgerald

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a report released on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($1.30) per share for the year, up from their previous estimate of ($3.00). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Cantor Fitzgerald also issued estimates for IDEAYA Biosciences’ FY2026 earnings at ($3.04) EPS.

IDYA has been the topic of several other reports. Citigroup reaffirmed a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Stephens reiterated an “overweight” rating and set a $45.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, The Goldman Sachs Group increased their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $45.50.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $32.14 on Monday. The company has a market cap of $2.82 billion, a P/E ratio of -17.28 and a beta of 0.14. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $33.64. The company has a 50-day moving average of $28.11 and a 200-day moving average of $24.21.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analysts’ expectations of $59.98 million.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in IDEAYA Biosciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock valued at $83,417,000 after acquiring an additional 14,535 shares during the period. Geode Capital Management LLC raised its position in shares of IDEAYA Biosciences by 1.6% in the second quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock valued at $44,424,000 after purchasing an additional 33,286 shares during the period. Fiera Capital Corp raised its position in shares of IDEAYA Biosciences by 20.0% in the third quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock valued at $50,011,000 after purchasing an additional 305,698 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of IDEAYA Biosciences by 4.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after buying an additional 50,000 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of IDEAYA Biosciences by 40.5% during the 3rd quarter. UBS Group AG now owns 1,056,577 shares of the company’s stock worth $28,749,000 after buying an additional 304,672 shares during the period. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.